ArticleMedicine2026
Impact of low-dose alteplase bridging therapy on outcomes after mechanical thrombectomy in patients with atrial fibrillation-associated acute stroke: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal alteplase dose for bridging therapy in atrial fibrillation related large vessel occlusion stroke is uncertain. We compared low-dose alteplase plus mechanical thrombectomy with standard-dose bridging and direct thrombectomy. This single-center retrospective cohort included all consecutive eligible patients (n = 375) treated between January 2021 and December 2024; no a priori sample size calculation was performed. Patients received low-dose alteplase 0.6 mg/kg plus thrombectomy (group A, n = 120), standard-dose 0.9 mg/kg plus thrombectomy (group B, n = 125), or direct thrombectomy without thrombolysis (group C, n = 130). Primary outcomes were successful reperfusion (mTICI 2b-3), 90-day functional independence (mRS 0-2), and symptomatic intracerebral hemorrhage. Secondary outcomes included early neurologic change, 72 hour National Institutes of Health Stroke Scale, mortality, and key procedural metrics. Multivariable logistic regression adjusted for age, severity, time metrics, occlusion site, and comorbidities. Baseline features were similar. Versus direct thrombectomy, low-dose bridging improved reperfusion (91.7% vs 84.6) and increased 90-day independence (58.3% vs 45.4). Early improvement and 72 hour National Institutes of Health Stroke Scale favored low-dose bridging. Symptomatic intracerebral hemorrhage was lower with low-dose versus standard-dose bridging (3.3% vs 6.4) and comparable to direct thrombectomy. Low-dose bridging also shortened puncture-to-reperfusion time. In adjusted models, low-dose bridging predicted 90 day independence (odds ratio 1.68) and lower odds of symptomatic hemorrhage than standard-dose (odds ratio 0.48). Low-dose alteplase bridging before thrombectomy improved efficacy and safety in atrial fibrillation related large vessel occlusion stroke and may be preferable for patients at higher bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.